1. Introduction {#sec1}
===============

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that is characterized by synovial inflammation and cartilage and bone destruction \[[@B1]\]. Interleukin- (IL-) 6 is implicated in RA pathogenesis \[[@B2], [@B3]\]. After binding to the IL-6 receptor (IL-6R), IL-6 mediates a systemic inflammatory response at cellular and organ-specific levels inducing acute phase reactant production in liver and a febrile response \[[@B4]\]. Furthermore, in concert with transforming growth factor beta (TGF-*β*), IL-6 promotes naïve T cells to preferentially differentiate into T helper (Th) 17 cells through a sequential engagement of IL-21 and IL-23. In addition, IL-6 inhibits the generation of regulatory T (Treg) cells. As such, IL-6 is involved in activation of both innate and adaptive immune cells and contributes to chronic inflammatory process in RA \[[@B5]--[@B7]\].

Tocilizumab (TCZ) is a humanized monoclonal antibody targeting the IL-6R, which blocks both soluble and membrane bound IL-6R. It is effective in RA treatment and frequently leads to disease remission \[[@B8]--[@B12]\]. However, as a significant subset of RA patients still do not respond to TCZ, it is of paramount importance to identify those patients who will clinically respond to TCZ before treatment initiation. Accordingly, several biomarkers have been explored as predictors of treatment response. Low baseline levels of serum IL-6 before TCZ treatment have been associated with the good efficacy at 4 weeks \[[@B13]\]. However, the clinical response at 4 weeks of treatment cannot be necessarily extrapolated into a long-term clinical response. Low baseline levels of soluble IL-6R (sIL-6R) may be a better marker for clinical response to TCZ \[[@B14]\].

As IL-6 is involved in Th17 generation, which contributes to RA pathogenesis, we hypothesized that the additional presence of cytokines involved in Th17 generation and activation might be associated with a worse clinical response to TCZ in RA patients.

2. Patients and Methods {#sec2}
=======================

2.1. Study Population {#sec2.1}
---------------------

This study was specifically designed as a substudy of the TCZ study (CWP-TCZ301, registered at [www.clinicaltrials.gov](https://www.clinicaltrials.gov/), [NCT01211834](https://clinicaltrials.gov/ct2/show/NCT01211834)), a 24-week, randomized, double-blinded, multicenter trial of TCZ in RA patients with an inadequate response to disease-modifying antirheumatic drugs (DMARDs). Patients were randomly assigned in a 1 : 1 ratio to receive intravenous infusion of TCZ 8 mg/kg or placebo every 4 weeks with stable dose of methotrexate (MTX) and/or other DMARDs. Patients who did not achieve a 20% improvement from baseline in both swollen joints count (SJC) and tender joints count (TJC) at week 16 were offered escape therapy. For inclusion, patients needed to be ≥18 years of age with moderate-to-severe active RA for ≥6 months. RA was diagnosed according to the revised 1987 American College of Rheumatology criteria. Active RA was defined by the presence of a SJC in six or more of 66 joints, TJC in eight or more of 68 joints, and C-reactive protein (CRP) level ≥1 mg/dL or erythrocyte sedimentation rate (ESR) ≥28 mm/h. Enrolled patients received stable dose of MTX with or without other DMARDs (hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide) for ≥8 weeks prior to study entry. Oral glucocorticoids (up to 10 mg/day prednisone or equivalent) and nonsteroidal anti-inflammatory drugs were allowed if the dose had been stable for ≥4 weeks prior to the randomization. If patients had received any biologic agents previously, those were stopped with appropriate washout periods (≥2 weeks for etanercept, ≥8 weeks for infliximab or adalimumab, ≥12 weeks for abatacept, and ≥36 weeks for rituximab). Forty-eight patients were enrolled in the TCZ arm. Of these, 44 patients who completed the 12-week treatment with TCZ and 12 age- and sex-matched healthy controls were included.

The protocol was approved by institutional review boards and ethics committees of Seoul National University Hospital, Seoul, Republic of Korea (1302-028-463). All patients gave informed consent. The study was conducted in full concordance with the principles of the Declaration of Helsinki and with the laws and the regulations of Korea.

2.2. Sample Collection and Assays {#sec2.2}
---------------------------------

All samples were immediately stored at −80°C until cytokine assay. Serum IL-6, sIL-6R, and rheumatoid factor (RF) were assayed using appropriate enzyme linked immunosorbent assays (ELISAs) (IL-6 and sIL-6R, eBioscience, San Diego, CA, USA, and RF, Nittobo, Tokyo, Japan). The levels of TNF-*α*, IL-17A, IL-21, and IL-23 were measured using a multiplex bead immunoassay with Luminex laser based fluorescent analytical test instrumentation (Merck-Millipore, Darmstadt, Germany). All assays were conducted in duplicate.

2.3. Statistical Analyses {#sec2.3}
-------------------------

Mann-Whitney*U* test was performed for group comparisons and Fisher\'s exact test was used for categorical variables. To examine the effect of baseline IL-17A levels on disease activity score 28 (DAS28) ESR response, analysis of covariance (ANCOVA) was used after adjusting for baseline DAS28 ESR, RF positivity, and levels of TNF-*α*, IL-21, and IL-23. A *P* value \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS statistics version 19 (IBM, Chicago, IL, USA) and graphics were generated in GraphPad Prism version 5 (La Jolla, CA, USA).

3. Results {#sec3}
==========

3.1. Study Population {#sec3.1}
---------------------

Clinical characteristics are shown in [Table 1](#tab1){ref-type="table"}. Patients were on average 52.2 years old, 88.6% were females, and RF was positive in 72.7%. Patients had moderate-to-severe RA for ≥6 months with the mean DAS28 ESR score (±SEM) of 6.12 ± 0.12 at baseline. The mean disease duration was 10.9 ± 1.2 years. All patients took MTX with the mean dose of 14.6 mg per week. In addition, 29.5% and 11.4% of patients received hydroxychloroquine and sulfasalazine, respectively. Furthermore, 6.8% received TNF-*α* inhibitors prior to commencement of the study.

3.2. Baseline Serum Cytokine Levels and Changes in DAS28 ESR in Patients Who Did and Did Not Achieve Remission at 12 Weeks of TCZ Therapy {#sec3.2}
-----------------------------------------------------------------------------------------------------------------------------------------

Among the 44 patients, 14 (31.8%) patients achieved DAS28 ESR remission at 12 weeks of TCZ therapy and 30 (68.2%) patients did not. At baseline, IL-17A levels were significantly lower in the remission group than in the nonremission group (3.50 ± 2.94 versus 7.34 ± 3.34 pg/mL; *P* \< 0.036). Levels of TNF-*α*, IL-6, sIL-6R, IL-21, and IL-23 did not differ between the groups ([Figure 1](#fig1){ref-type="fig"}).

3.3. Baseline Clinical Characteristics and Serum Cytokines Levels in the IL-17A Low Group and the IL-17A High Group {#sec3.3}
-------------------------------------------------------------------------------------------------------------------

In the 12 healthy controls, IL-17A was detected only in one individual at 0.23 pg/mL. In RA patients, baseline IL-17A levels appeared to follow a bimodal distribution ([Figure 2](#fig2){ref-type="fig"}). Accordingly, RA patients were divided into an IL-17A low group and an IL-17A high group using the baseline mean + 3 standard deviation (SD) IL-17A level (i.e., 0.22 pg/mL) in the healthy controls as a cut-off value. Baseline clinical characteristics were comparable between the IL-17A low group (*n* = 21) and the IL-17A high group (*n* = 23). Disease duration and activity expressed as DAS28 ESR did not differ between the groups. Only RF positivity was higher in the IL-17A high group ([Table 1](#tab1){ref-type="table"}). At baseline, TNF-*α*, IL-21, and IL-23 levels were significantly higher in the IL-17A high group than in the IL-17A low group (*P* = 0.001, *P* = 0.003, and *P* = 0.002, resp.). Levels of IL-6 and sIL-6R at baseline were not significantly different between the groups ([Table 2](#tab2){ref-type="table"}).

3.4. Low Baseline Levels of IL-17A Were Associated with Better Clinical Response to TCZ Treatment {#sec3.4}
-------------------------------------------------------------------------------------------------

A significantly higher proportion of patients in the IL-17A low group achieved DAS28 ESR remission at 12 weeks as compared to the IL-17A high group (47.6 versus 17.4%; *P* = 0.032 by Fisher\'s exact test) ([Figure 3(a)](#fig3){ref-type="fig"}). Individual DAS28 ESR scores in each group at baseline and 12 weeks are depicted in [Figure 3(b)](#fig3){ref-type="fig"}. In the IL-17A low group, the mean DAS28 score improved from 6.07 ± 0.20 at baseline to 2.93 ± 0.25 at 12 weeks, whereas the mean DAS28 score in the IL-17A high group declined from 6.16 ± 0.14 to 3.49 ± 0.21. The improvement in the DAS28 ESR was significantly better in the IL-17A low group compared to the IL-17A high group at 12 weeks (3.15 ± 0.21 versus 2.66 ± 0.17; *P* = 0.045) after adjusting for baseline DAS28 ESR, RF positivity, and levels of TNF-*α*, IL-21, and IL-23. After 12 weeks, 18 (85.7%) of 21 patients in the IL-17A low group and 21 (91.3%) of 23 patients in the IL-17A high group continued the therapy with TCZ over a period of 24 weeks. TCZ was discontinued in five patients due to adverse effects. At 24 weeks, the mean DAS28 ESR score in the IL-17A low and high groups was 2.57 ± 0.21 and 3.10 ± 0.22, respectively. DAS28 ESR improved from baseline significantly more in the IL-17A low group compared to the IL-17A high group at 24 weeks (3.47 ± 0.23 versus 2.99 ± 0.22; *P* = 0.046) as well ([Figure 3(c)](#fig3){ref-type="fig"}).

3.5. Effect of TCZ on the Levels of Th17-Related Cytokines after Treatment {#sec3.5}
--------------------------------------------------------------------------

Levels of IL-6 and IL-17A did not significantly change during treatment. However, levels of IL-21 and IL-23 were decreased significantly at 12 weeks in both DAS28 remission and nonremission patients (all *P* \< 0.005). Interestingly, serum levels of TNF-*α* did not change at 12 weeks in the remission group, whereas they increased in the nonremission group. Although baseline sIL-6R levels were not significantly different in both remission and nonremission patients, they significantly increased after TCZ treatment irrespective of the remission status (all *P* \< 0.001) (Supplemental Figure  1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2015/487230>).

4. Discussion {#sec4}
=============

To the best of our knowledge, the current study is the first to show the association between the low baseline IL-17A and better clinical response to TCZ treatment in RA patients who had an inadequate response to DMARDs.

In the present study, DAS28 improvement was significantly better in the IL-17A low group than in the IL-17A high group at 12 and 24 weeks of TCZ treatment. Only baseline IL-17A levels differed between patients who did and did not achieve remission, whereas other clinical and laboratory features including baseline sIL-6R levels did not differ. This is in contrast to a previous report that low baseline levels of sIL-6R were associated with better clinical response to TCZ \[[@B14]\]. The difference could be explained in part by the different demographic and clinical features of the studied patients; the patients in the prior study had a lower disease activity (mean DAS28 ESR 5.1) with relatively short disease duration (mean 4.5 years) and received infrequently concomitant MTX (33%) as compared with the patients in our study. As such, it is conceivable that RA progression might be associated with emergence of Th17 cells and that those RA patients with additional IL-17 signature respond less to TCZ, which targets IL-6 signaling. It would be interesting to define whether cytokine profiles change over time as RA progresses. Furthermore, the prior observation that young age (\<55 years), baseline CRP \> 1 mg/dL, and no history of cerebrovascular disease were associated with European League Against Rheumatism remission at 6 months in RA patients treated with TCZ \[[@B15]\] could not be confirmed in our study.

IL-6 is required for IL-21 production by naïve T cells. Both IL-6 and IL-21 lead to B-cell activation that contributes to RA progression \[[@B16]\]. In addition, IL-21 induces the expression of IL-23R. Subsequently, IL-21 and IL-23 along with TGF-*β* induce expression of ROR*γ*t, which is the transcription factor for Th17 differentiation, and subsequent IL-17 production \[[@B17]\]. As expected, the IL-17A high patients had also increased levels of IL-21 and IL-23 ([Table 2](#tab2){ref-type="table"}), consistent with the prior reports that Th17 are enriched in a subset of RA patients \[[@B18], [@B19]\]. Therefore, it is conceivable that blockade of the IL-6 signaling by TCZ decreases production of both IL-21 and IL-23 \[[@B17]\].

Interestingly, the levels of TNF-*α* and IL-6 were not associated with better TCZ treatment response ([Figure 1](#fig1){ref-type="fig"}). Instead, only low IL-17A levels were associated with better clinical response to TCZ, suggesting that the additional presence of IL-17 or even Th17 cells lead to worse response to IL-6 blockade. Indeed, an incomplete response to TNF-*α* inhibitors was reportedly associated with high baseline IL-17 levels in RA patients \[[@B20], [@B21]\]. Similarly, patients with type I interferon high signature may not respond to rituximab treatment \[[@B22]\]. Therefore, RA is a heterogeneous disease group encompassing different subsets with varying immunologic abnormalities \[[@B23]\] and patients with elevated IL-17A levels might represent a unique RA subset.

In the present study, significant difference in DAS response between the IL-17A high and low groups might indicate additional contribution of IL-17A to the total inflammatory burden in RA. This might explain the modest treatment effect of secukinumab, anti-IL-17A monoclonal antibody, in treatment of RA \[[@B24]\]. It is tempting to speculate that blockade of IL-17 in addition to IL-6 or TNF-*α* inhibition might improve the clinical response in those RA patients with high baseline IL-17A levels.

5. Conclusions {#sec5}
==============

Low baseline serum levels of IL-17A are associated with better clinical response to TCZ in RA patients. A larger prospective study is needed to confirm the predictive value of IL-17A levels in treatment response. Measuring IL-17A levels might help develop a new personalized RA treatment strategy.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplemental Figure 1. Changes in serum cytokine levels in DAS28 ESR remission patients and non-remissions at 12 weeks after tocilizumab treatment. The changes in serum levels of TNF-α (A), IL-6 (B), sIL-6R (C), IL-17A (D), IL-21 (E) and IL-23 (F) in 14 DAS28 ESR remission patients and 30 non-remission patients at 12 weeks after tocilizumab treatment (IL-6 and sIL-6R levels were shown respectively at 8 weeks and 24 weeks because we did not measure at 12 weeks). Dot represents each person and bars represent the mean value and SEM. The *p*-value was assessed by Mann-Whitney U test or Wilcoxon\'s signed rank test.
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![Baseline IL-17A levels are lower in the patients who reached DAS28 ESR remission at 12 weeks of tocilizumab treatment. Baseline serum levels of TNF-*α* (a), IL-6 (b), sIL-6R (c), IL-21 (e), and IL-23 (f) did not differ between the patients with DAS28 ESR remission (*n* = 14) and nonremission (*n* = 30) at 12 weeks of tocilizumab treatment. Only IL-17A levels were significantly lower in the remission patients (d). Of note, sIL-6R levels were not checked in healthy controls. Dot represents each person and bars represent the mean value and SEM. *P* value was assessed by Mann-Whitney*U* test. HC = healthy controls and N/A = not assayed.](JIR2015-487230.001){#fig1}

![Bimodal distribution of IL-17A levels in the patients. Upper normal value of IL-17A level was defined as the mean serum IL-17A levels + 3SD in healthy controls (*n* = 12). IL-17A levels of RA patients were divided into the IL-17A low (*n* = 21) and high (*n* = 23) groups. Vertical line marks the cut-off value (i.e., upper normal value of IL-17A levels in the healthy controls). RA = rheumatoid arthritis; HC = healthy controls.](JIR2015-487230.002){#fig2}

![Low baseline levels of IL-17A are associated with DAS28 ESR remission at 12 weeks of tocilizumab treatment. A significantly higher proportion of patients in the IL-17A low group achieved DAS28 remission at 12 weeks as compared to the IL-17A high group (47.6 versus 17.4%, *P* = 0.032) by Fisher\'s exact test (a). Individual DAS28 ESR improved in both groups. However, the improvement in DAS28 ESR was more profound in the IL-17A low group with higher remission rate (b). The improvement in DAS28 ESR was better in the IL-17A low group at 12 weeks (^∗^ *P* = 0.045) and 24 weeks (^∗∗^ *P* = 0.046) after tocilizumab treatment after adjusting for baseline DAS28 ESR, RF positivity, and levels of TNF-*α*, IL-21, and IL-23. Data represents mean value ± SEM (c).](JIR2015-487230.003){#fig3}

###### 

Baseline clinical characteristics of the IL-17A low group and the IL-17A high group.

                                          All (*n* = 44)   IL-17A low (*n* = 21)   IL-17A high (*n* = 23)   *P* value
  --------------------------------------- ---------------- ----------------------- ------------------------ -----------
  Age, years                              52.2 ± 1.6       50.9 ± 1.9              53.5 ± 2.5               0.285
  Female (%)                              39 (88.6)        19 (90.5)               20 (87.0)                1.000
  Disease duration, years                 10.9 ± 1.2       10.8 ± 1.9              11.0 ± 1.5               0.716
  RF positivity (%)                       32 (72.7)        11 (52.4)               21 (91.3)                0.006
  ESR (mm/h)                              51.7 ± 3.6       48.4 ± 5.9              54.7 ± 4.4               0.217
  CRP (mg/dL)                             2.6 ± 0.4        2.5 ± 0.4               2.6 ± 0.6                0.733
  DAS28 ESR                               6.12 ± 0.12      6.07 ± 0.20             6.16 ± 0.14              0.549
  Prednisolone users (%)                  36 (81.8)        19 (90.5)               17 (73.9)                0.245
  Prednisolone equivalent dose (mg/day)   3.8 ± 0.4        4.2 ± 0.6               3.3 ± 0.6                0.302
  Concomitant DMARDs                                                                                         
   MTX users (%)                          44 (100)         21 (100)                23 (100)                 1.000
   MTX (mg/wk)                            14.6 ± 0.5       14.4 ± 0.7              14.7 ± 0.6               0.887
   HCQ (%)                                13 (29.5)        5 (23.8)                8 (34.8)                 0.426
   SSZ (%)                                5 (11.4)         5 (23.8)                0 (0)                    0.013
  Previous TNF-*α* inhibitors (%)         3 (6.8)          3 (14.3)                0 (0)                    0.100

Data are presented as mean (±SEM) for continuous data and number (percentage) for categorical variables. RF = rheumatoid factors; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; DAS = disease activity score; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; HCQ = hydroxychloroquine; SSZ = sulfasalazine; TNF-*α* = tumor necrosis factor-alpha.

###### 

Comparison of baseline serum cytokine levels in the IL-17A low group and the IL-17A high group.

                   IL-17A low (*n* = 21)   IL-17A high (*n* = 23)   *P* value
  ---------------- ----------------------- ------------------------ -----------
  IL-17A levels    0.01 ± 0.00             11.69 ± 4.43             \<0.001
  TNF-*α* levels   6.38 ± 1.23             33.84 ± 11.00            0.001
  IL-6 levels      8.46 ± 1.14             8.77 ± 1.14              0.879
  sIL-6R levels    162.94 ± 7.68           170.37 ± 7.09            0.672
  IL-21 levels     4.34 ± 1.48             140.05 ± 50.97           0.003
  IL-23 levels     1.23 ± 0.54             15.11 ± 6.45             0.002

Data are presented as mean (±SEM) for continuous variables. TNF-*α* = tumor necrosis factor-alpha; IL = interleukin; sIL-6R = soluble interleukin 6 receptor.
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